Repligen (NASDAQ:RGEN) Shares Gap Up to $157.48

Repligen Co. (NASDAQ:RGEN) gapped up before the market opened on Tuesday . The stock had previously closed at $157.48, but opened at $166.49. Repligen shares last traded at $171.99, with a volume of 139,951 shares.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on RGEN shares. Stifel Nicolaus upped their target price on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. KeyCorp upped their target price on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $196.70.

Repligen Stock Down 2.0 %

The business has a fifty day moving average of $185.86 and a 200 day moving average of $173.52. The stock has a market cap of $9.37 billion, a price-to-earnings ratio of 233.14, a P/E/G ratio of 5.61 and a beta of 1.02. The company has a debt-to-equity ratio of 0.26, a current ratio of 7.02 and a quick ratio of 5.75.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The firm had revenue of $155.74 million for the quarter, compared to the consensus estimate of $155.38 million. During the same quarter in the prior year, the company posted $0.68 earnings per share. The firm’s revenue was down 16.6% on a year-over-year basis. On average, equities analysts predict that Repligen Co. will post 1.46 earnings per share for the current year.

Insider Buying and Selling at Repligen

In other Repligen news, COO James Bylund sold 4,373 shares of the stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the transaction, the chief operating officer now owns 14,135 shares in the company, valued at $2,799,860.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, COO James Bylund sold 4,373 shares of Repligen stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the transaction, the chief operating officer now owns 14,135 shares in the company, valued at approximately $2,799,860.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the transaction, the director now owns 87,367 shares in the company, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock worth $5,039,532 over the last 90 days. Insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Repligen by 152.1% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 146 shares during the period. Park Place Capital Corp increased its holdings in shares of Repligen by 90.2% during the 3rd quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 120 shares during the period. Principal Securities Inc. bought a new position in shares of Repligen during the 4th quarter worth about $48,000. Signaturefd LLC increased its holdings in shares of Repligen by 44.1% during the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 86 shares during the period. Finally, CWM LLC increased its holdings in shares of Repligen by 19.9% during the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 60 shares during the period. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.